Guobang Pharma Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 5.2yrs |
Recent management updates
Recent updates
Guobang Pharma Ltd. (SHSE:605507) Screens Well But There Might Be A Catch
Dec 09
Calculating The Fair Value Of Guobang Pharma Ltd. (SHSE:605507)
Aug 26These 4 Measures Indicate That Guobang Pharma (SHSE:605507) Is Using Debt Extensively
Jul 24Guobang Pharma Ltd. (SHSE:605507) Analysts Just Cut Their EPS Forecasts Substantially
May 21Fewer Investors Than Expected Jumping On Guobang Pharma Ltd. (SHSE:605507)
Apr 18We Think Guobang Pharma (SHSE:605507) Is Taking Some Risk With Its Debt
Mar 25CEO
Guobang Pharma has no CEO, or we have no data on them.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CFO, Financial Director | 5.2yrs | CN¥1.55m | 0.90% CN¥ 103.6m | |
| Chairman of the Board | 5.2yrs | CN¥2.13m | 9.92% CN¥ 1.1b | |
| Director | 5.2yrs | CN¥1.55m | 1.35% CN¥ 155.5m | |
| Supervisory Board Chairman | 5.2yrs | no data | 0.31% CN¥ 36.3m | |
| Independent Director | 5.2yrs | CN¥140.00k | no data | |
| Independent Director | 5.2yrs | CN¥140.00k | no data |
5.2yrs
Average Tenure
57yo
Average Age
Experienced Board: 605507's board of directors are considered experienced (5.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 10:38 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Guobang Pharma Ltd. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhu Chen | Citic Securities Co., Ltd. |
| Kai Wang | Citic Securities Co., Ltd. |
| Jiarui Lu | Guosen Securities Co., Ltd. |